Hinova Pharmaceuticals Inc. A (SHG:688302) — Market Cap & Net Worth
Market Cap & Net Worth: Hinova Pharmaceuticals Inc. A (688302)
Hinova Pharmaceuticals Inc. A (SHG:688302) has a market capitalization of $486.83 Million (CN¥3.33 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #12571 globally and #3720 in its home market, demonstrating a 13.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hinova Pharmaceuticals Inc. A's stock price CN¥33.60 by its total outstanding shares 99015598 (99.02 Million). Also see Hinova Pharmaceuticals Inc. A (688302) total assets for a full breakdown of the balance sheet.
Hinova Pharmaceuticals Inc. A Market Cap History: 2022 to 2026
Hinova Pharmaceuticals Inc. A's market capitalization history from 2022 to 2026. Data shows growth from $584.20 Million to $486.83 Million (2.50% CAGR). Also see 688302 cash flow metrics for how efficiently the company converts equity into cash flow.
Hinova Pharmaceuticals Inc. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hinova Pharmaceuticals Inc. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 688302 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1212.97x
Hinova Pharmaceuticals Inc. A's market cap is 1212.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $584.20 Million | $1.65 Million | -$301.51 Million | 353.88x | N/A |
| 2024 | $444.96 Million | $366.84K | -$199.50 Million | 1212.97x | N/A |
Competitor Companies of 688302 by Market Capitalization
Companies near Hinova Pharmaceuticals Inc. A in the global market cap rankings as of September 24, 2026. Review Hinova Pharmaceuticals Inc. A tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hinova Pharmaceuticals Inc. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Hinova Pharmaceuticals Inc. A Historical Marketcap From 2022 to 2026
Between 2022 and today, Hinova Pharmaceuticals Inc. A's market cap moved from $584.20 Million to $ 486.83 Million, with a yearly change of 2.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥486.83 Million | -31.67% |
| 2025 | CN¥712.43 Million | +60.11% |
| 2024 | CN¥444.96 Million | -41.02% |
| 2023 | CN¥754.45 Million | +29.14% |
| 2022 | CN¥584.20 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Hinova Pharmaceuticals Inc. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $486.83 Million USD |
| MoneyControl | $486.83 Million USD |
| MarketWatch | $486.83 Million USD |
| marketcap.company | $486.83 Million USD |
| Reuters | $486.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hinova Pharmaceuticals Inc. A
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501… Read more